<p>Once hailed as the cornerstone of modern medicine, antibiotics are now facing a critical reckoning as resistance outpaces innovation. The relentless rise of multidrug-resistant (MDR) pathogens, particularly the notorious ESKAPE group, has rendered many conventional antibiotics increasingly ineffective, transforming once-manageable infections into formidable clinical challenges. In response, researchers are pursuing diverse and inventive strategies to rejuvenate the antibiotic pipeline. Pharmacognostic exploration continues to uncover rare molecular scaffolds from nature’s reservoirs, which are refined through synthetic tailoring to enhance potency, stability, and pharmacokinetics. Simultaneously, computational drug design is accelerating discovery by predicting molecular interactions with precision. At the same time, genetic engineering unlocks dormant microbial biosynthetic pathways to generate novel compounds through pathway refactoring and combinatorial biosynthesis. Nanotechnology adds another powerful dimension, enabling innovative delivery platforms that enhance drug penetration, minimise off-target effects, and bypass bacterial defences. Meanwhile, bacterial membrane vesicles are emerging as innovative carriers capable of delivering antimicrobial payloads directly to resistant cells. Supporting these scientific advances, evolving regulatory frameworks—such as the FDA’s QIDP designation and the EMA’s PRIME program—are accelerating the clinical trials, development, and approval of promising candidates, revitalising investment and momentum in antibacterial innovation. This convergence of natural discovery, synthetic chemistry, computational modelling, genetic engineering, nanotechnology, and progressive policy marks a pivotal turning point in antimicrobial therapeutics, offering real hope of outpacing resistance and securing the future of effective treatments against MDR infections.</p> Graphical abstract <p></p>